Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity

Acta Pharmacologica Sinica

Volumn 30, Issue 1, 2009, Pages 61-69

  Chen, Ronald J Y ^a   Chung, Tse Yu ^a   Li, Feng Yin ^a   Lin, Nan Hei ^a   Tzen, Jason T C ^a,b  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

Cardiac therapeutic effect; Ginsenoside; Molecular modeling; Na+ K+ ATPase; Steric hindrance

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CARDIAC GLYCOSIDE; DIGOXIN; DISACCHARIDE; GINSENOSIDE; GINSENOSIDE PPD; GINSENOSIDE PPT; GINSENOSIDE R1; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RB 3; GINSENOSIDE RC; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; GINSENOSIDE RH 1; GINSENOSIDE RH 2; MONOSACCHARIDE; OLEANOLIC ACID; OUABAIN; PSEUDOGINSENOSIDE; UNCLASSIFIED DRUG; CARBOHYDRATE; ENZYME INHIBITOR; HERBACEOUS AGENT;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; GINSENG; MOLECULAR MODEL; PANAX NOTOGINSENG; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CHINESE MEDICINE; DRUG ANTAGONISM; HUMAN; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; BINDING SITES; CARBOHYDRATES; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; GINSENOSIDES; HUMANS; MEDICINE, CHINESE TRADITIONAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OUABAIN; PANAX; PANAX NOTOGINSENG; PROTEIN CONFORMATION; SODIUM-POTASSIUM-EXCHANGING ATPASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64849089057     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.6     Document Type: Article

References (32)

1. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, et al. Modulating angiogenesis: the yin and the yang in ginseng. Circulation 2004; 110: 1219-25.
2. Lei XL, Chiou GC. Cardiovascular pharmacology of Panax notoginseng (Burk) F. H. Chen and Salvia miltiorrhiza. Am J Chin Med 1986; 14: 145-52.
3. Wei JX, Du YC. Modern science research and application of Panax notoginseng. Kunming: Yunnan Science and Technology Press;1996 (in Chinese).
4. Cicero AF, Vitale G, Savino G, Arlet R. Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. Phytother Res 2003; 17: 174-8.
5. Dong TT, Cui XM, Song zH, zhao KJ, Ji zN, Lo CK, et al. Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents. J Agric Food Chem 2003; 51: 4617-23.
6. Leung KS, Chan K, Bensoussan A, Munroe MJ. Application of atmospheric pressure chemical ionisation mass spectrometry in the identification and differentiation of Panax species. Phytochem Anal 2007; 18: 146-50.
7. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterifcation with fatty acid. J Pharmacol Sci 2004; 95: 153-7.
8. Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007; 13: 381-404.
9. zhu S, zou K, Cai S, Meselhy MR, Komatsu K. Simultaneous determination of triterpene saponins in ginseng drugs by high-performance liquid chromatography. Chem Pharm Bull 2004; 52: 995-8.
10. Dan M, Su M, Gao X, zhao T, zhao A, Xie G, et al. Metabolite profiling of Panax notoginseng using UPLC-ESI-MS. Phyto-chemistry 2008; 69: 2237-44.
11. Jiang Y, Liu W, Wang XM, zhong GG, zhang WJ, Chen L, et al. Calcium channel blockade and anti-free-radical actions of panaxatriol saponins in cultured myocardiocytes. Acta Pharmacol Sin 1996; 17: 138-41.
12. Li-Saw-Hee FL, Lip GY. Digoxin revisited. QJM 1998; 91: 259- 64.
13. 2+-ATPase enriched nerve-ending plasma membranes. Brain Res 1982; 235: 387-92.
14. Goldberg H, Fernandez A. Simplified method of the estimation of inorganic phosphorus in body fluids. Clin Chem 1966; 12: 871-82.
15. Morth JP, Pedersen BP, Toustrup-Jensen MS, Sørensen TL, Petersen J, Andersen JP, et al. Crystal structure of the sodium-potas sium pump. Nature 2007; 450: 1043-9.
16. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comp Chem 1983; 4: 187-217.
17. +-ATPase play a key role in ouabain binding. J Biol Chem 2003; 278: 47240-4.
18. Qiu LY, Krieger E, Schaftenaar G, Swarts HG, Willems PH, De Pont JJ, et al. Reconstruction of the complete ouabain-binding pocket of Na,K-ATPase in gastric H, K-ATPase by substitution of only seven amino acids. J Biol Chem 2005; 280: 32 349-55.
19. Dixon SL, Merz KM Jr. One-dimensional molecular representations and similarity calculations: methodology and validation. J Med Chem 2001; 44: 3795-809.
20. Rao SN, Head MS, Kulkarni A, LaLonde JM. Validation studies of the site-directed docking program LibDock. J Chem Inf Model 2007; 47: 2159-71.
21. Diller DJ, Merz KM Jr. High throughput docking for library design and library prioritization. Proteins 2001; 43: 113-24.
22. Willet P, Barnard JM, Downs GM. Chemical similarity searching. J Chem Inf Comput Sci 1998; 38: 983-96.
23. Schultheis PJ, Wallick ET, Lingrel JB. Kinetic analysis of oua-bain binding to native and mutated forms of Na, K-ATPase and identification of a new region involved in cardiac glycoside interactions. J Biol Chem 1993; 268: 22 686-94.
24. Kobashi K, Akao T. Relation of intestinal bacteria to pharmacological effects of glycosides. Biosci Microflora 1997; 16: 1-7.
25. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003; 31: 1065-71.
26. Wang JK, Portbury S, Thomas MB, Barney S, Ricca DJ, Morris DL, et al. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc Natl Acad Sci USA 2006; 103: 10 461-6.
27. +-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol Sin 2007; 28: 609-15.
28. zhang YG, Liu TP. Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. Acta Pharmacol Sin 1996; 17: 44-8.
29. Tian J, Fu F, Geng M, Jiang Y, Yang J, Jiang W, et al. Neuropro tec-tive effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. Neurosci Lett 2005; 374: 92-7.
30. zhou XM, Cao YL, Dou DQ. Protective effect of ginsenoside-Re against cerebral ischemia/reperfusion damage in rats. Biol Pharm Bull 2006; 29: 2502-5.
31. Yuan QL, Yang CX, Xu P, Gao XQ, Deng L, Chen P, et al. Neuroprotective effects of ginsenoside Rb1 on transient cerebral ischemia in rats. Brain Res 2007; 1167: 1-12.
32. Chen LM, zhou XM, Cao YL, Hu WX. Neuroprotection of ginsenoside Re in cerebral ischemia-reperfusion injury in rats. J Asian Nat Prod Res 2008; 10: 439-45.